Abstract:Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a real pandemic. After a median incubation period of 5 days, the disease occurs in different stages, inducing upper and lower airway responses in mild disease (80–90% of patients) and progressing to bilateral pneumonia in severe disease (10–20%) ( 1 – 3 ). A subgroup of patients with severe COVID-19 develops acute respiratory distress syndrome, requiring mechanical ventilation on intensive care. COVID-19 patients with preexisting comorbid conditions such as chronic respiratory diseases have worse disease outcomes, including a higher incidence of the need for hospitalization, ICU admission, and mortality ( 3 , 4 ). However, it remains to be further investigated how preexisting chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and their treatment might modify the risk for SARS-CoV-2 infection and development of COVID-19. Approximately 300 million individuals worldwide have asthma ( 5 ). Considering that a significant proportion of individuals with asthma is confronted with COVID-19, it is crucial to understand which asthma patients are particularly at risk and how inhaled corticosteroids (ICS)—the cornerstone of asthma treatment—may influence morbidity and mortality associated with COVID-19. Long-term treatment with systemic corticosteroids (e.g., in transplant patients) is immunosuppressive, increasing the risk and severity of viral infections. Because of the potential risk for worse disease outcomes, the World Health Organization does not recommend systemic corticosteroid treatment in COVID-19 ( 6 ), unless if indicated for other reasons such as acute asthma or COPD exacerbations requiring a short course of oral corticosteroids. These recommendations have caused doubt and uncertainty among patients with asthma and physicians on whether ICS therapy should be maintained during this pandemic. However, withdrawal of ICS treatment puts asthma patients at risk of severe exacerbations. A recent meta-analysis on COVID-19 outcomes in patients with chronic respiratory diseases using ICS concluded that there is currently insufficient evidence to abandon the well-established ICS treatment in asthma ( 7 ). There is thus an urgent need to elucidate demographic and clinical characteristics that determine disease outcomes of COVID-19 in asthma, to investigate the impact of ICS and to unravel the underlying pathogenic mechanisms.

Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients

Effect of SARS-CoV-2 infection on asthma patients

Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid

Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks

Network-based analysis between SARS-CoV-2 receptor ACE2 and common host factors in COVID-19 and asthma: Potential mechanistic insights

Exploration of Potential Biomarkers and Mechanisms for COVID-19 and Asthma Based on Microarray Analysis

A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis

Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights

Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19

Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.

Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis

Comorbid Asthma Decreased the Risk for COVID-19 Mortality in the United Kingdom: Evidence Based on a Meta-Analysis

Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients

One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

Potential Protective Factors for Allergic Rhinitis Patients Infected with COVID-19

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Genomic analysis of severe COVID-19 considering or not asthma comorbidity: GWAS insights from the BQC19 cohort

Is Asthma An Exclusionary Condition For Sars-Cov-2 Infection In China? -The Relationship Between Asthma And Covid-19

Asthma as a risk factor and allergic rhinitis as a protective factor for COVID-19 severity: a case-control study

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?